Ceribell Beats Q2 Revenue, Raises 2026 Outlook to $114M-$117M
CBLL sits 78% above its 52-week low of $10.85.
Summary
Ceribell delivered a strong Q2 with revenue of $28.1M, up 33% year-over-year and ahead of the $27.3M consensus. The beat was driven by new account growth and higher utilization, while gross margin surged to 92% on cost cuts and a one-time tariff refund. Losses widened more than expected—$0.51 per share vs. the $0.47 estimate—but the market will focus on the raised full-year revenue guide to $114M-$117M. This follows a Q1 where revenue grew 29% but losses also expanded; the raised outlook signals accelerating top-line momentum. The upcoming NTAP effective date for delirium monitoring on October 1 adds a concrete catalyst for further adoption.
At the time of this announcement, CBLL was trading at $19.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $732.3M. The 52-week trading range was $10.85 to $24.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.